161 First Street
About CrestovoCrestovo was launched to advance the years of foundational clinical research and development of the company’s founder and scientific advisor Dr. Thomas J. Borody, and academic collaborators, Dr. Alexander Khoruts and Dr. Michael Sadowsky. Their collective work has validated orally-administered, full-spectrum bacterial composition products across a variety of serious diseases and medical needs, including recurrent Clostridium difficile infection (CDI, also commonly referred to as C. difficile or C. diff).
Thomas J. Borody, M.D.
Interim CEO & COO: Joseph Lobacki
Please click here for Crestovo's job opportunities.
3 articles with Crestovo
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”
Two privately-held biotechs have merged to tackle recurrent C. difficile infections.
Crestovo Doses Patients In PRISM 3, A Clinical Trial Of CP101, A Microbiome Therapy For The Prevention Of Recurrent Clostridium Difficile Infection